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A B S T R A C T
Background: Doxorubicin (DOX) is a chemotherapeutic drug limited in its usefulness by an adverse side eﬀect,
cardiotoxicity. The mechanisms leading to this detrimental occurrence are not completely clear, and lately many
authors focused their attention on the possible role of microRNAs (miRNAs), small regulators of cardiovascular
functions, in this phenomenon. Notably, these molecules recently emerged also as potential circulating bio-
markers of several cardiac diseases. Thus, the aim of this study was the simultaneous investigation of circulating
and cardiac tissue miRNAs expression upon DOX treatment in vivo.
Methods: Twenty C57BL/6 female mice were administered with 24mg/Kg cumulative dose of DOX or saline
(CTRL) for 2 weeks. Echocardiography was performed at baseline and at the end of treatment (T1). Plasma and
heart samples were collected at T1, separating atria from left (LV) and right (RV) ventricles, and miRNAs ex-
pression was tested by RT-qPCR-based arrays. All putatively DOX-regulated candidates were then validated by
single assays in vivo and then evaluated also in murine immortalized cardiomyocytes (HL-1) treated with 1 μM
DOX for 24 h. In the end, bioinformatics target prediction was performed for all DOX-miRNAs.
Results: Cardiotoxicity onset was diagnosed upon impairment of six cardiac functional parameters in DOX-
treated mice at T1. Samples collection, followed by screening and validation steps, identiﬁed eleven miRNAs
dysregulated by the drug in plasma, while seven resulted as altered in separate heart chambers. Interestingly,
miR-34a-5p and miR-451a showed a dysregulation in both plasma and tissue samples of DOX-administered
animals, whereas ﬁve additional miRNAs presented chamber speciﬁc modulation. Of note, in vitro experiments
showed a very modest overlap with in vivo results. Bioinformatics prediction analysis performed on miR-34a-5p
and miR-451a identiﬁed several putative targets presenting no signiﬁcant association with cardiotoxicity.
Anyhow, the same analyses, conducted by combining all miRNAs regulated by DOX in each heart chamber,
evidenced a possible dysregulation of the adherens junctions gene network, known to be involved in the onset
and progression of dilated cardiomyopathy, an established detrimental side eﬀect of the drug.
Conclusions: This is the ﬁrst work investigating miRNAs regulation by DOX both in plasma and heart districts of
treated animals. Our results indicate a strong association of miR-34a-5p and miR-451a to DOX-induced cardi-
otoxicity. In addition, the observed altered expression of diverse miRNAs in separated cardiac chambers hints at
a speciﬁc response to the drug, implying the existence of diﬀerent players and pathways leading to dysfunction
onset.
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1. Introduction
Doxorubicin (DOX) is a potent chemotherapeutic agent belonging to
the family of anthracycline drugs, discovered in the late 1960s and
isolated from Streptomyces peucetius. It is used to treat many types of
tumours such as breast, liver, colon cancer, lymphomas, and leukemia
[1].
Doxorubicin treatment quickly led to an improvement in the sur-
vival rates of oncologic patients, thus, at length, showing its toxic side
eﬀects on many organs, particularly on heart. Indeed, the major lim-
iting factor of DOX administration relies in its dose-related cardio-
toxicity [2], ranging from subclinical ventricular dysfunction to severe
cardiomyopathy, leading to heart failure, cardiac transplantation and,
eventually, death [3]. Cardiotoxicity can occur early during treatment
or after several years from administration, and individual risk assess-
ment is very diﬃcult. Despite the lack of a universally accepted deﬁ-
nition, it is described as a decline of left ventricular ejection fraction
(LVEF) of more than 10 percentage points to a value< 53% (normal
reference value for two-dimensional echocardiography), according to a
recent expert consensus paper [4]. The approaches currently used to
detect and monitor cardiotoxicity are echocardiography, nuclear ima-
ging, and, when indicated, endomyocardial biopsy [5,6], all techniques
leading to a late diagnosis. In the last few years, Brain Natriuretic
Peptide (BNP) and cardiac Troponins (cTns) have been adopted [7,8] as
additional cardiac damage/dysfunction indicators. MicroRNAs
(miRNAs) are small endogenous non-coding RNAs of 21–24 nucleo-
tides, acting as post-transcriptional gene regulators via inhibition and/
or degradation of target messenger RNAs (mRNAs). MiRNAs play an
important role in diﬀerent biological processes including proliferation,
development, diﬀerentiation and cell death [9]. In addition, several
miRNAs are implicated in the regulation of heart development from
embryonic to adult stage and their dysregulation leads to various heart
diseases such as cardiomyopathy, heart failure, arrhythmias and car-
diac hypertrophy [10]. In recent years, numerous groups investigated
the potential use of circulating miRNAs as possible speciﬁc biomarkers
and therapeutic targets of cardiac maladies [11]. To date, though, there
are only few articles about circulating and tissue miRNAs association
with DOX-induced cardiotoxicity. In addition, data derived from these
studies are heterogeneous, in particular concerning cardiotoxicity
evaluation methods and the selection of the samples used for the ana-
lyses [12]. On these bases, we aimed at identifying speciﬁc plasma and
heart-chambers miRNAs associated with DOX-induced cardiotoxicity in
vivo during the acute phase of treatment.
2. Materials and methods
2.1. Animal model
Twenty C57BL/6 female mice (Charles River Laboratories), aged 10
weeks old, were administered either with saline (CTRL, n= 10) or
doxorubicin hydrochloride (DOX, n= 10, cumulative dose 24mg/kg,
Sigma-Aldrich) by six intraperitoneal injections (4 mg/kg) 3 times a
week for 2 weeks (Fig. 1), as previously reported [13]. The study was
carried out in strict accordance with the recommendations of the Guide
for the Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Committee on the Ethics of
Animal Experiments of the University of Milan and by the Italian
Ministry of Health (approval number 379/2015-PR). Female mice were
chosen in order to create an animal model as close as possible to female
breast cancer patients.
2.2. Cardiotoxicity assessment
Before treatment (baseline) and after the last DOX-injection (T1)
cardiac function was monitored by echocardiography using a VEVO
2100 high-resolution imaging system (VisualSonics). Induction of
anaesthesia was performed using 2% isoﬂurane (Merial) mixed with
100% oxygen (2min) in an induction chamber. Mice were then placed
on a heat pad in the supine position and kept at 37 °C to minimize
ﬂuctuations of body temperature. Data acquisition was performed in
mice lightly anesthetized with 0.5%–1% isoﬂurane, in order to main-
tain heart rate ≥450 beats/min. Two-dimensional short-axis M-mode
echocardiography was performed to evaluate the following parameters:
left ventricular ejection fraction (LVEF), left ventricular fractional
shortening (LVFS), left ventricular end-systolic volume (LVSV), left
ventricular end-diastolic volume (LVDV), internal end-systolic and end-
diastolic diameters (LVSD, LVDD).
2.3. Plasma cardiac troponin
Cardiac Troponin I was measured in plasma samples at T1 using the
Mouse Cardiac Tn-I (High Sensitivity) kit (Life Diagnostics), following
the manufacturer’s instructions.
2.4. Plasma and cardiac tissue collection
Blood was collected after sacriﬁce at T1 using EDTA-coated tubes,
and immediately centrifuged to separate plasma as previously described
[14]. At the same time, cardiac chambers (atria, LV and RV) were
isolated after heart excision, and immersed in Allprotect Tissue Reagent
(Qiagen) following manufacturer’s indications to prevent RNA de-
gradation. Due to technical limitations, right and left atria were col-
lected as a single chamber. All samples were stored at −80 °C until
further use.
2.5. Cell culture
Immortalized murine cardiomyocytes (HL-1) were grown in
Claycomb complete medium (Sigma Aldrich), according to vendor’s
instructions. Cells were plated in six-well plates (250.000/well); the
following day, fresh medium was added with either 1 μM (ﬁnal con-
centration) DOX or an equivalent volume of sterile PBS. After 24 h,
supernatants and cells were collected. Supernatants were centrifuged at
500×g for 10’ at 4 °C to remove cells, and then at 16000×g for 10’ at
4 °C to remove remaining debris.
Fig. 1. Experimental Design. Treatment protocol for our animal model of DOX-
induced cardiotoxicity. Arrows indicate each single 4mg/kg intraperitoneal
DOX/saline injection. Black vertical bars indicate experimental endpoints when
echocardiography (Echo) was performed and samples (plasma, hearts) collec-
tion took place. Each group was composed of ten animals.
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2.6. Total RNA puriﬁcation
RNA puriﬁcation from plasma (200 μL/sample) was conducted
using TRIzol (Life Technologies) following a modiﬁed protocol for li-
quid samples [15]. Total RNA was resuspended in 50 μl of RNAse-free
water. RNA isolation from cardiac chambers was performed by homo-
genizing the tissues in 1ml/100mg of TRIzol reagent using a Tissue-
Lyser (Qiagen), according to manufacturer’s instructions, similarly to
total RNA from HL-1 cells. Heart and HL-1 RNA pellets were re-
suspended in 32 μl RNAse-free water and quantiﬁed using a NanoDrop
One (ThermoFisher Scientiﬁc). All samples were stored at−80 °C until
further use.
2.7. Circulating microRNAs screening
Circulating miRNAs expression proﬁles were conducted at T1 using
the TaqMan Rodent MicroRNA A Array v2.0 (Applied Biosystems),
following manufacturer’s protocol for liquid samples. The screening
was performed on four chosen samples from each group. Data were
analyzed using ExpressionSuite v1.0.3 dedicated software
(LifeTechnologies), and Global Normalization method was applied. All
miRNAs presenting Ct values> 32 were considered as not expressed.
2.8. MicroRNAs screening of cardiac tissues
Tissue miRNAs expression proﬁles were conducted at T1 by
OpenArray® Real-Time PCR System according to manufacturer’s in-
structions (Applied Biosystems), using a custom plate with 224 candi-
date microRNAs (supplementary table A1). The screening was per-
formed on four chosen samples from each group. RT was conducted
using the TaqMan Advanced miRNA cDNA Synthesis Kit. After pre-
ampliﬁcation and dilution, a mixture composed of 2.5 μl of each sample
and 2.5 μl of Taq Man OpenArray Real Time PCR master mix (Applied
Biosystems) was dispensed on a OpenArray plate using the AccuFill
automated sample loading system (Applied Biosystems), and run using
a QuantStudio 12k Flex Real Time PCR System. Data analysis was
conducted using a cloud-based Thermo Fisher Scientiﬁc proprietary
software (Thermo Fisher cloud, https://apps.thermoﬁsher.com/apps/).
Samples presenting a Cq value>35, an ampliﬁcation score (Amp
Score)< 1.24, and a Cq conﬁdence (Cq conf) value<0.8 were re-
jected.
2.9. Single microRNA assays
MicroRNAs reverse transcription was performed using TaqMan
Advanced miRNA cDNA Synthesis Kit (Life Technologies) starting from
either 2 μl (liquid samples) or 10 ng (tissues and cells) of total RNA.
Expression levels of selected miRNAs were evaluated using single
TaqMan Advanced miRNA assays (Life Technologies), according to
manufacturer’s protocol. RT-qPCR experiments on plasma were nor-
malized using miR-27b-3p, while on tissues were normalized on miR-
186-5p levels, in both cases basing on screening results as previously
described [14–16]. Results from HL1 cells were normalized using miR-
16.
2.10. DOX-miRNA target prediction
In order to identify putative mRNA targets for miR-34a-5p and miR-
451a, we performed a target prediction analysis by the means of the
Cystoscape v.3.5.0 [17] plug-in ‘Cytargetlinker v.4.0.1’ [18], taking
advantage of the miRTarBase database v.6.1 [19], which gathers the
largest amount of experimentally validated miRNA-target interactions.
Then, the functional analysis of the identiﬁed miRNA target genes was
performed by the Cystoscape plugin ‘ClueGO v.2.5.2’ [20], using the
Gene Ontology Biological Process as ontology reference. Combined
target prediction of district speciﬁc DOX-regulated miRNAs was
performed using DIANA-miRPath v3. 0 (http://diana.imis.athena-
innovation.gr/DianaTools/index.php) [21].
2.11. Statistical analysis
Two-way ANOVA was used in combination with Tukey's test to
compare the mean levels of the six measured echocardiographic para-
meters across two conditions (CTRL vs. DOX) and two time points
(baseline vs. T1). The tests were performed by using R (version 3.5.0)
native statistical functions. The diﬀerences in miRNAs expression level
were assessed by either t-test or Kruskal–Wallis test, when appropriate,
after evaluation of normal distribution of the data (GraphPad Prism 5
Software). All P values< 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Evaluation of cardiotoxicity
Since the principal purpose of the present study was to identify
potential dysregulation of miRNAs upon DOX-induced cardiac dys-
function, we ﬁrstly assessed the presence of cardiotoxicity by echo-
cardiography (supplementary ﬁgure A1). No diﬀerences were evident
between the two groups at baseline. Contrarily, we found that heart
impairment was evident in drug treated animals at T1. In particular,
DOX mice presented a signiﬁcant reduction of LVEF (-6.1%, p= 0.01)
and LVFS (-5.4%, p=0.03) when compared to the CTRL group, and a
concomitant increase of LVSD (+ 0.3mm, p < 0.01) and LVSV
(+4.3 μl, p < 0.01) (Fig. 2 and supplementary table A2). Besides,
despite not being statistically signiﬁcant, both LVDD (+ 0.1mm,
p=0.38) and LVDV (+3.9 μl, p= 0.37) showed an increasing trend in
treated mice. Doxorubicin administered animals showed signiﬁcant
modiﬁcations in all six parameters during treatment. In particular, both
LVEF (-8.5%, p < 0.01) and LVFS (-7.9%, p < 0.01) showed a de-
crease, while LVSD (+0.4mm, p < 0.01), LVSV (+6.2 μl, p < 0.01),
LVDD (+ 0.2mm, p < 0.01) and LVDV (+8.5 μl, p < 0.01) pre-
sented an increase vs baseline values. Of note, we observed statistically
signiﬁcant variations also in CTRL animals through time in regard of
two parameters, LVFS (-5.2%, p=0.04) and LVSD (-0.2 mm,
p < 0.01). In addition, plasma cardiac troponin I was measured at T1
as marker of cardiac damage. Interestingly, no diﬀerences were ob-
served between DOX and CTRL animals (supplementary ﬁgure A2).
3.2. Plasmatic microRNAs proﬁling and validation
With the aim of identifying plasma miRNAs potentially regulated by
DOX, we conducted an array-based screening comparing CTRL (n=4)
and treated (n= 4) samples. We observed forty miRNAs potentially
regulated (p < 0.05) at T1 between DOX and CTRL groups (supple-
mentary table A3), among which all miRNAs showing a fold
change>2 and<0.6 were selected for validation by single assay on
all samples (n= 10/group). Moreover, a few additional miRNAs were
analysed, basing on previously known involvement in cardiac diseases:
miR-1-3p, -133a-3p and miR-499a-5p [14].
Our results showed eleven miRNAs regulated by DOX at T1. In
particular miR-32-5p, -34a-5p, -34b-3p, -34c-5p, -133a-3p, -301b-3p,
-499-5p were upregulated, while miR-93-5p, -140-3p, -431-5p, and
-451a were downregulated in DOX-administered mice vs. CTRL (Fig. 3
and supplementary table A4).
3.3. Cardiac tissue microRNAs proﬁling and validation
Concurrently, we validated the expression of miRNAs in cardiac
tissues obtained from the same animals, keeping the three diﬀerent
cardiac districts (LV, RV and atria) separated. Our screening showed
ﬁfteen miRNAs putatively presenting a dysregulation in heart chambers
from DOX animals (supplementary table A5). After validation, seven
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miRNAs presented a diﬀerential expression among the cardiac districts
obtained from drug-treated mice vs CTRL. In particular, two miRNAs
showed a dysregulation in more than one chamber. Indeed, miR-34a-5p
was upregulated in atria and downregulated in both ventricles (LV and
RV) of DOX treated mice. At the same time, miR-451a showed a de-
creased expression in both atria and RV (Fig. 4 and supplementary table
A6). Diﬀerently, three miRNAs presented a dysregulation only in the
atria: two (miR-128-3p and miR-190a-5p) were increased by DOX,
while miR-484a was diminished in treated animals. At the same time,
both miR-146a-5p and -351 were downregulated in RV (Fig. 5 and
supplementary table A6).
3.4. DOX-miRNA expression in vitro
We decided to investigate whether a murine cardiomyocyte model
could produce results comparable to our in vivo experiments. Thus, we
analysed the expression of cardiac DOX-miRNAs in both cells lysates
and supernatants from HL-1 cells treated with doxorubicin (1 μM) for
24 h. Interestingly, miR-451a showed a downregulated expression (vs.
CTRLs) in supernatants from DOX-treated HL-1 cells, (supplementary
ﬁgure A3). Conversely, cellular expression analysis indicated ﬁve
miRNAs as upregulated by DOX in HL-1 cells (supplementary ﬁgure A4
and supplementary table A7): miR-34a-5p, -34b-3p, -34c-5p, -140-3p,
and miR-451a.
3.5. Target prediction of DOX-miRNAs
We performed target prediction analysis for the two miRNAs pre-
senting a DOX-driven dysregulation in all chambers, miR-34a-5p and
miR-451a. Our results showed 16 high- and 39 low-conﬁdence (basing
on the number of the number of validation techniques) targets for miR-
34a-5p, and 5 high- and 43 low-conﬁdence targets for miR-451a (sup-
plementary table A8). There was no evident overlapping between the
two groups both in terms of target genes and of predicted targeted gene
networks (supplementary ﬁgures A5 and A6). Nevertheless, two pre-
vious unrelated works involving the 2 miRNAs showed their possible
involvement (upon miR-34a-5p increase and miR-451a decrease) in
dilated cardiomyopathy, a known long-term side eﬀect of DOX-induced
cardiotoxicity [22,23]. This “paucity of results” prompted us to expand
our analyses to all other miRNAs regulated by DOX in the diﬀerent
heart districts: miR-128-3p, miR-190a-5p and miR-484a in the atria,
and miR-146a-5p and miR-351 in RV. The combination of these
miRNAs with miR-34a-5p and miR-451a evidenced their possible in-
volvement in several molecular networks in both atria and RV (sup-
plementary table A9). Interestingly, among these, we observed the
presence of 3 gene networks (Rap1 and Notch signaling in atria, ad-
herens junction in RV), involved in the regulation of intercellular
connections and known to be dysregulated in dilated cardiomyopathy
and other cardiac diseases [24].
Fig. 2. Cardiac dysfunction assessment. Cardiac functional parameters were analyzed in controls (CTRL, blue) and DOX (red) mice at baseline and T1. LVEF= left
ventricular ejection fraction; LVFS= left ventricular fractional shortening; LVSD= left ventricular internal end-systolic diameter; LVDD= left ventricular internal
end-diastolic diameter; LVSV= left ventricular end-systolic volume, LVDV= left ventricular end-diastolic volume. Data are depicted as dot plots, lines represent
mean value ± SD. * = p < 0.05; **= p < 0.01; *** = p < 0.001. CTRL n=10; DOX n=10 (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article).
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4. Discussion
This is the ﬁrst work reporting the eﬀects of acute DOX treatment on
the levels of miRNAs evaluated in both plasma and speciﬁc heart
chambers from the same animals. In particular, the diﬀerential drug-
response of each speciﬁc cardiac district represents an element of no-
velty in this kind of studies, particularly in the miRNA ﬁeld.
Interestingly, echocardiography showed the expected presence of car-
diac dysfunction in our murine model of DOX-induced cardiotoxicity
[13]. Surprisingly, though, CTRL mice showed a quite modest but sig-
niﬁcant alteration in both LVFS and LVSD, hinting at possible detri-
mental cardiac eﬀects of mock treatment combined with physiological
stress due to manipulation and stabulation. Despite that, when com-
paring CTRL and DOX animals at T1, cardiotoxicity symptoms were
evident only in the latter group, characterized by a signiﬁcant decrease
in both LVEF and LVFS, and by the increase in systolic LV diameters and
volumes. In this setting, we decided to assess the expression of plasma
miRNAs upon cardiac dysfunction onset. Our screening, and the fol-
lowing validation step, evidenced the dysregulation of eleven miRNAs,
seven of which displayed a positive regulation by DOX, while four
decreased when we compared treated vs. CTRL mice. Of note, three
(miR-34a-5p, -133a-3p, -499-5p) of the regulated circulating miRNAs
were, to some extent, previously associated with DOX-induced cardio-
toxicity [25–27]. Increased plasma levels of these miRNAs were also
shown by us and others also in relation with other types of cardiac
injury (miR-133a-3p and miR-499-5p) [14,28] and with heart re-
modelling (miR-34a) [29], hinting at a speciﬁc role in cardiac response
to damage and triggered here by DOX. Notably, two other members of
the miR-34 family, miR-34b-3p and -34c-5p, were already known to be
regulated by the drug in the heart [12], the former being modulated
also in circulating form [30], in line with our results. Among the other
DOX-miRNAs, miR-32-5p was never associated to cardiotoxicity, and
was recently described as involved in aortic calciﬁcation [31]. Inter-
estingly, similarly to what observed in our setting, plasma levels of miR-
301b-3p were shown to be increased in patients with acute myeloid
leukaemia (AML) after standard chemotherapy [32]. Among the DOX-
decreased miRNAs, circulating miR-93-5p is of particular interest be-
cause of its previously proposed role as exosome-vehiculated attenuator
of cardiac damage [33]. Thus, its decrease upon DOX administration
could contribute to the onset and progression of cardiotoxicity. Of note,
increased plasma levels of miR-140-3p were associated to the onset of
coronary events, but only in the very early phases [34], possibly ex-
plaining the discrepancies with our observations. As for miR-431-5p, no
previous data are available about its possible role as marker of cardiac
injury.
The results obtained from the separate heart districts evidenced
seven DOX-regulated miRNAs. Among them, two miRNAs were dysre-
gulated upon drug administration both at tissue and at circulating le-
vels, miR-34a-5p and miR-451a. Of note, the former did not show a
uniform response to DOX treatment in all heart chambers. Indeed,
while the results from treated atria are in line with the current literature
[12], both RV and LV showed an unexpected downregulation of this
miRNA. Intriguingly, our results could indicate a diﬀerential DOX eﬀect
on those players regulating miR-34a expression in the three separate
heart districts, although the exact mechanisms at the base of this phe-
nomenon remain elusive. Diﬀerently from miR-34a-5p, miR-451a pre-
sented a uniform trend of regulation both in RV and in atria, where it
exhibited a marked decrease in treated animals. Interestingly, miR-
Fig. 3. Plasma miRNAs regulation upon Doxorubicin treatment. Eleven miRNAs showed dysregulated expression upon DOX-treatment (vs. controls) at T1. Data are
depicted as scatter plots and expressed as mean fold change ± SD vs. CTRL, arbitrarily set to one. Controls (CTRL): blue dots, Dox-treated (DOX): red dots. * =
p < 0.05; **= p < 0.01; *** = p < 0.001. CTRL n=10, DOX n=10 (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article).
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451a was shown to be a candidate marker of chemoresistance in triple-
negative breast cancer patients administered with DOX [35], and de-
creased levels of this miRNA were associated to hypertrophic cardio-
myopathy, one of the main diseases associated with cardiotoxicity [36].
Among the miRNAs regulated by DOX in heart tissues, only miR-146a
had a previous history of “suggested” regulation by the drug in rodent
hearts [30], even if its modulation in the cardiac tissue was never
shown. In addition, miR-128 and miR-190 were described as implicated
in the onset of heart impairment. Indeed, miR-128 deletion was cor-
related with a reduction of the levels of ﬁbrosis and attenuation of
cardiac dysfunction in response to MI [37], suggesting a possible role
for this miRNA also in the DOX-triggered heart remodelling. Con-
versely, miR-190 down-regulation was associated with transverse aortic
constriction-induced hypertrophy [38], seemingly in contrast with our
observations, limited as they are to the acute phase of the treatment.
None of the other miRNAs showing a modulation by DOX in the three
heart districts presented an association with cardiac failure in the lit-
erature.
Our in vitro results clearly demonstrate that cellular models are not
completely reliable in recapitulating in vivo experiments. Indeed, only
two miRNAs showed DOX-induced modulation both in vitro and in vivo,
miR-34a-5p and miR-451a. Of note, while DOX-induced down-
regulation of the latter in HL-1 supernatants was in line with its murine
plasma counterpart, it showed an opposite trend when comparing
hearts and cells. Interestingly, miR-34a-5p displayed a decreased ex-
pression upon DOX treatment in HL-1 cells, a result in line with the
atrial origin of these cardiomyocytes.
The natural step following the validation of DOX-regulated miRNAs
in murine tissues was target identiﬁcation. Our bioinformatics predic-
tion performed for miR-34a-5p and -451a did not produce any appre-
ciable result in terms of (possibly) modulated genes and gene networks.
Interestingly, though, the same analyses performed combining all DOX-
modulated miRNAs (regardless of heart chamber speciﬁcity), clearly
evidenced a possible dysregulation in the physiological expression of
cardiac adherens junctions, important players in the onset and pro-
gression of cardiotoxicity-related cardiomyopathies. These results could
open the way to new investigations aiming at shedding some light on
the many still unveiled mechanism leading to DOX-triggered heart
dysfunction.
We should acknowledge some limitations of our work. We decided
to rely on echocardiography assessment of cardiac dysfunction, instead
of histology, in order to use all our tissue samples to evaluate miRNA
expression. In addition, we did not observe any change in circulating
cardiac troponin I, a known marker of cardiac damage. In a previous
paper from our group [13], we showed an increase of plasma cTnI one
week after the end of DOX administration, using the same animal
model. Thus, it is possible to speculate that the two-weeks-time-frame
(T1) presented in this work is too short to appreciate a signiﬁcant in-
crease in TnI levels (at least in our experimental conditions). Female
reproductive hormones were previously proposed to be associated with
cardioprotective states [39]. However, although several mechanisms
have been suggested for this phenomenon, no study elucidated the in-
ﬂuence of ﬂuctuating hormones on cardiac tissue remodelling. Note-
worthy, estrogen was demonstrated to have no signiﬁcant eﬀects on LV
diastolic function in premenopausal woman [40]. In addition, it was
shown that estrous cycle does not inﬂuence cardiac ischemia-reperfu-
sion injury in rats [41]. Since oestrous cycle was not evaluated in our
animals, though, its possible inﬂuence on cardiotoxicity cannot be ex-
cluded.
Fig. 4. MiRNAs regulated in multiple cardiac chambers upon Doxorubicin treatment. Two miRNAs showed dysregulated expression upon DOX-treatment (vs.
controls) in atria, LV and RV at T1. Data are depicted as scatter plots and expressed as mean fold change ± SD vs. Controls (CTRL), arbitrarily set to one. Controls
(CTRL): blue dots, Dox-treated (DOX): red dots. * = p < 0.05; **= p < 0.01. CTRL n=5, DOX n=5 (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article).
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5. Conclusions
In conclusion, despite the limited overlap in terms of drug-response
between plasma and heart districts, our results suggest an important
role for speciﬁc miRNAs both as biomarkers and as mechanistic factors
in the DOX-induced and chamber-speciﬁc heart dysfunction onset. In
particular, both miR-34a-5p and miR-451a seem to represent the master
players in this still poorly deﬁned and complicated network of path-
ways triggered by the drug. Future studies focusing on identiﬁcation of
chamber speciﬁc triggers and validation of their targets will help un-
ravelling their exact role in the pathology. The results obtained in the
three considered cardiac chambers could lead to a better understanding
of how the investigated drug aﬀects speciﬁc functional districts of the
heart. Indeed, this could pave the way to new therapeutic and diag-
nostic strategies to prevent and contrast DOX-induced cardiotoxicity.
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